Homepage / Technology / Silicon Valley's biggest start-up factory is making a bet on biotech, but it's not an obvious fit
Amazon says this Prime Day was its biggest shopping event ever Kudlow says President Trump is 'so dissatisfied' with China trade talks that he is keeping the pressure on As stocks regain their footing, an ominous warning looms Goldman Sachs downgrades Clorox to sell, says valuation is 'unsustainably high' How Satya Nadella has spurred a tripling of Microsoft's stock price in just over four years Kudlow says economic growth could top 4% for 'a quarter or two,' more tax cuts could be coming The one chart that explains Netflix’s stunning comeback US housing starts plunge 12% in June to a nine-month low Aerospace titans Boeing and Airbus top $110 billion in orders at Farnborough Target uses Prime Day to its advantage, logging its 'biggest online shopping day' so far this year Billionaire Marc Lasry sees bitcoin reaching up to $40,000 as it becomes more mainstream and easier to trade These are the 10 US airports where you're most likely to be hacked Amazon shares slightly higher as investors await Prime Day results Wreck of Russian warship found, believed to hold gold worth $130 billion A bullish ‘phenomenon’ in bond market is weeks away from fading, top credit strategist says Stocks making the biggest moves premarket: MS, GOOGL, TXN, UAL, NFLX & more Twitter shares up 50% since late April means most upside priced in, analyst says in downgrade EU fines Google $5 billion over Android antitrust abuse Mortgage applications fall 2.5% as buyers struggle to find affordable homes America may not have the tools to counter the next financial crisis, warn Bernanke, Geithner and Paulson Investors are getting spooked as the risk of a no-deal Brexit rises EU expected to fine Google $5 billion over Android antitrust abuse Ex-FBI chief James Comey urges Americans to vote for Democrats in midterm elections Elon Musk apologizes to British cave diver following baseless 'pedo guy' claim Disney, Comcast and Fox: All you need to know about one of the biggest media battles ever Xiaomi shares notch new high after Hong Kong, mainland China stock exchanges reach agreement The trade war is complicating China's efforts to fix its economy European markets set for a strong open amid earnings; Google in focus Hedge fund billionaire Einhorn places sixth in major poker tournament The biggest spender of political ads on Facebook? President Trump Asian stocks poised to gain after Fed's Powell gives upbeat comments; dollar firmer Stocks are setting up to break to new highs Not all FAANG stocks are created equal EU ruling may be too little, too late to stop Google's mobile dominance Cramer explains how Netflix's stock managed to taper its drop after disappointing on earnings Airbnb condemns New York City's 'bellhop politics,' threatens legal retaliation Amazon sellers say they were unfairly suspended right before Prime Day, and now have two bad choices Investor explains why 'duller' tech stocks can have better returns than 'high-flying' tech names Elon Musk is 'thin-skinned and short-tempered,' says tech VC Texas Instruments CEO Brian Crutcher resigns for violating code of conduct Google Cloud Platform fixes issues that took down Spotify, Snapchat and other popular sites Uber exec: We want to become the 'one stop' transportation app 'What a dumb hearing,' says Democrat as Congress grills tech companies on conservative bias Amazon shares rebound, report says Prime Day sales jumped 89 percent in first 12 hours of the event How to put your medical history on your iPhone in less than 5 minutes Investment chief: Watch these two big events in 2018 Even with Netflix slowing, the market rally is likely not over Cramer: Netflix subscriber weakness debunks the 'sky's the limit' theory on the stock Netflix is looking at watch time as a new area of growth, but the competition is stiff Why Nobel laureate Richard Thaler follows Warren Buffett's advice to avoid bitcoin Rolls-Royce is developing tiny 'cockroach' robots to crawl in and fix airplane engines After Netflix plunge, Wall Street analysts forecast just tame returns ahead for the once high-flying FANG group Roku shares rise after analyst raises streaming video company's price target due to customer growth China is investing 9 times more into Europe than into North America, report reveals Amazon says US Prime Day sales 'so far bigger than ever' as glitch is resolved Netflix is on pace for its worst day in two years US lumber producers see huge opportunity, rush to expand San Francisco to consider tax on companies to help homeless Homebuilder sentiment, still high, stalls as tariffs, labor and land drive up costs Powell backs more rate hikes as economy growing 'considerably stronger' Netflix history is filled with big stock declines – like today – followed by bigger rebounds Intel shares get downgraded by Evercore ISI due to rising competition from Nvidia, AMD Petco aims to reinvent the pet store with something you can't buy online Genetic testing is coming of age, but for consumers it's buyer beware Tech 'FAANG' was the most-crowded trade in the world heading into the Netflix implosion, survey shows Netflix weak subscriber growth may indicate a 'maturity wall' that could whack the stock even more: Analyst This chart may be predicting the bull market's demise Wall Street says Netflix's stock plunge is a ‘compelling’ buying opportunity because the streaming giant ‘never misses twice’ Tesla sinks after Musk tweets, again Boeing announces new division devoted to flying taxis Stocks making the biggest move premarket: NFLX, UNH, GS, AMZN, WMT & more Deutsche Bank downgrades Netflix, but says big subscriber miss is not 'thesis changing' IBM is experimenting with a cryptocurrency that’s pegged to the US dollar North Korea and Zimbabwe: A friendship explained Virgin Galactic spinoff Orbit to launch rockets from the UK with space deal Artificial intelligence will create more jobs than it destroys? That’s what PwC says ‘Treasonous’ Trump and ‘Putin’s poodle:' Scathing headlines follow the Trump-Putin summit China’s fintech companies offer ‘enormous’ opportunity, investment manager says Trump's performance at summit with Putin was 'unprecedented,' experts say Walmart and Microsoft link up on cloud technology as they both battle Amazon European stocks seen mixed amid earnings; Fed’s Powell to address Congress How I knew I should quit my day job and run my start-up full-time: Viral website founder China's stocks have been trounced, but the trade war may ultimately be good news for those shares Billionaire tech investor Peter Thiel bets on crypto start-up Block.one Asian shares subdued open after mixed close on Wall Street; energy stocks under pressure Amazon cloud hits snags after Amazon Prime Day downtime Netflix isn't doomed by one quarter unless people start questioning the long-term investor thesis Tech stocks set to sink on Tuesday after rough evening for ‘FANG’ Netflix plummets after missing big on subscriber growth This wristband lets humans control machines with their minds The U.S. has a rocky history convincing Russia to extradite computer criminals Amazon suffers glitches at the start of Prime Day Jeff Bezos is now the richest man in modern history 'The United States has been foolish': Read Trump and Putin's full exchange Goldman Sachs recommends these 5 highly profitable companies — including Nvidia — to combat rising inflation Goldman Sachs releases 'tactical' stock picks for this earnings season Three red flags for Netflix ahead of its earnings report The bond market may be raising recession fears, but don't expect one anytime soon Cramer: Banks are 'making fortunes' but are still as hated as they were during the financial crisis Putin told Trump at summit: Russia never meddled in US election


Silicon Valley's biggest start-up factory is making a bet on biotech, but it's not an obvious fit

Y Combinator, Silicon Valley’s best known start-up accelerator, thinks it has found a new type of biotechnology start-up.

Life-sciences companies come with a high risk of failure—often, the science behind a proposed invention isn’t entirely proven, and turns out not to work. Because of this risk, the traditional way to fund early-stage life sciences companies is for a landmark East Coast investor, such as Third Rock or Flagship, to take a huge equity stake in the business and replace the founder with a seasoned executive. In exchange, it pumps tens of millions of dollars into the company over many years. It often takes more than a decade to generate a return.

But YC is betting that biotech start-ups that use the latest computer science technologies such as machine learning, will grow much more quickly than their counterparts, and thus should be funded more like tech start-ups.

A classic example is YC’s first biotech company: Ginkgo Bioworks, which bills itself as scaling the process of organism engineering using “software and hardware automation.” After graduating from YC in 2014, the company went on to raise more than $150 million from tech investors including Felicis Ventures and Data Collective.

Biotech is is now a serious category for the fund. Y Combinator is about to add another part-time partner with health and biotech expertise to its ranks, alongside existing partner Elizabeth Iorns (Altman declined to name them, as the plans have not yet been finalized).

“When I took over YC in 2014 I made a list of things I wanted to get into,” said the company’s president Sam Altman. “Health and synthetic biologies were two of the categories.”

Y Combinator’s interest in biotech came at an ideal time.

In the past few years, Sand Hill Road investors ranging from Andreessen Horowitz to GV (formerly Google Ventures) are eyeing companies that bring advanced computing to areas like disease detection and drug development, which they hope will scale at fraction of the cost than traditional biotech companies.

CRV investor George Zachary is also a convert, recently shifting his focus from tech to companies that are “advancing health through computer science.”

Altman said it wasn’t always this way. “When we started funding bio companies, Sand Hill Road hadn’t decided they liked it yet,” he explained. “But it turns out that there was interest in a few years from West Coast tech.”‘

But so far, YC’s biotech founders have found only mixed success appealing to Silicon Valley.

YC graduate Ethan Perlstein is currently fundraising for Perlara, a start-up that is focused on finding treatments for rare diseases. In his experience, it has been a challenge for many Y Combinator alumni in the sector to raise their first big round of venture financing. Sand Hill Road’s investors will open the door, he said, but few are willing to write a big check for a first round.

YC’s partners acknowledged the challenge, but said it isn’t unique to its health care companies.

“I think that raising a true series A round is challenging for a lot of companies right now, which isn’t specific to therapeutics,” explained Iorns, CEO of a start-up called Science Exchange and a part-time partner at Y Combinator.

Iorns said Y Combinator companies that have an “element of machine learning or computational biology” are actually among the most sought-after overall. That’s in large part due to the success of cancer drug development start-up Stemcentrx, which sold in 2016 for $10.2 billion to AbbVie. Stemcentrx, which was funded in 2008, claimes to use “new technologies and paradigms” to discover new drug therapies.

But biotech is an uneasy fit for a culture steeped in software, and online companies that can turn on a dime.

Unlike traditional biotech start-ups, which remain in stealth mode for years until they get strong scientific evidence to back up their claims, start-ups that get accepted into the Y Combinator’s must demo a minimally viable product in 3 months.

Some outsiders are skeptical.

“YC wants to fund tech people that do biotech, rather than embracing what it takes to do biotech,” said Ryan Bethencourt, venture partner with IndieBio, an accelerator program that focuses on synthetic biology companies.

“But YC doesn’t have the expertise to tackle an established industry with regulatory hurdles, pricing and reimbursement complexities,” he added. “They haven’t changed the model enough to reliably build therapeutics companies.”

Altman said that Y Combinator recognizes that health companies have some unique challenges relative to tech — and that “it takes longer” than other sectors. But he also believes there are some aspects of the business that can be done quickly, such as getting introductions to potential customers for early pilots. He also thinks the opportunity is too huge to pass up.

“I’m super excited about the entrepreneurial focus in health and biotech,” he said. “It’s one of these mind-blowing moments where we’re not that far away from an A.I. doctor.”

Source: Tech CNBC
Silicon Valley's biggest start-up factory is making a bet on biotech, but it's not an obvious fit

Comments are closed.